Mucosal Melanoma clinical trials

Explore recruiting mucosal melanoma clinical trials.

Recruiting mucosal melanoma studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Mucosal Melanoma trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Open-Label, Multicenter, Cohort Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6

Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase II multicentric study: efficacy evaluation of neo-adjuvant treatment associated with maintenance therapy by anti-PD1 immunotherapy on disease-free-survival (DFS) in patients with resectable mucosal melanoma (IMMUQ)

France

Therapeutic exploratory (Phase II) EU CTIS Study details

As Phase I/II, multi-center, open label study of DYP688 in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas

Germany, Spain, France, Netherlands

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

NEOREM/NEO-1 - NEOREM : Neo-adjuvant Adaptive Master Trial for Localized Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / NEO-1 : Neo-adjuvant intratumoral Anti-CTLA4 + Anti-PD1 treatment in patients with localized melanoma

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A first study in humans testing the safety and effects of KUP-101A in patients with certain advanced solid cancers

Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Mucosal Melanoma trials by city

Mucosal Melanoma in Toronto Mucosal Melanoma in Vancouver Mucosal Melanoma in Montreal Mucosal Melanoma in Calgary Mucosal Melanoma in Edmonton Mucosal Melanoma in Ottawa Mucosal Melanoma in Winnipeg Mucosal Melanoma in Quebec City Mucosal Melanoma in Hamilton Mucosal Melanoma in Kitchener Mucosal Melanoma in London Mucosal Melanoma in Halifax Mucosal Melanoma in New York Mucosal Melanoma in Los Angeles Mucosal Melanoma in Chicago Mucosal Melanoma in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease